Hence, the cut-off level of IL-6 as a tumor biomarker must be sufficiently high in order to only diagnose the patients with malignancies and not patient with inflammatory conditions, and still relatively low in order to detect all patients with malignancies. The gene discussed is IL6; the disease is cancer.